Trypanosoma cruzi
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Trypanosoma cruzi as ChEMBL target CHEMBL368. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Trypanosoma cruzi matters
Trypanosoma cruzi is reviewed as Trypanosoma cruzi; the current evidence base includes 120 approved drugs, 82303 compounds, and 3284 assays, with lead potency reaching pChEMBL 10.8.
Trypanosoma cruzi
Review this target as Trypanosoma cruzi.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 120 approved drugs, 82303 compounds, and 3284 assays for this target. The dominant activity type is IC50. CHEMBL3259946 is the current potency anchor at pChEMBL 10.8.
Use CHEMBL3259946 as the tractability anchor when discussing potency (pChEMBL 10.8).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Trypanosoma cruzi matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3259946
|
10.8 | EC50 | — |
|
|
No preferred name
CHEMBL110
|
10.4 | EC50 | Approved |
|
|
No preferred name
CHEMBL2448735
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL3259944
|
9.9 | EC50 | — |
|
|
No preferred name
CHEMBL2448747
|
9.7 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
NIFURTIMOX
CHEMBL290960
|
2020 |
|
|
BENZNIDAZOLE
CHEMBL110
|
2017 |
|
|
MILTEFOSINE
CHEMBL125
|
2014 |
|
|
DELAMANID
CHEMBL218650
|
2014 |
|
|
POSACONAZOLE
CHEMBL1397
|
2005 |
|
|
VORICONAZOLE
CHEMBL638
|
2002 |
|
|
AZELASTINE
CHEMBL639
|
1996 |
|
|
DOCETAXEL
CHEMBL3545252
|
1995 |
|
|
ITRACONAZOLE
CHEMBL64391
|
1992 |
|
|
OXICONAZOLE NITRATE
CHEMBL1200836
|
1988 |
|
|
TERCONAZOLE
CHEMBL1714574
|
1987 |
|
|
AMIODARONE
CHEMBL633
|
1985 |
|
|
PENTAMIDINE
CHEMBL55
|
1984 |
|
|
TIOCONAZOLE
CHEMBL1200438
|
1983 |
|
|
ECONAZOLE
CHEMBL808
|
1982 |
|
|
KETOCONAZOLE
CHEMBL157101
|
1981 |
|
|
CLOTRIMAZOLE
CHEMBL104
|
1975 |
|
|
MICONAZOLE
CHEMBL91
|
1974 |
|
|
MICONAZOLE NITRATE
CHEMBL1559
|
1974 |
|
|
AMPHOTERICIN B
CHEMBL267345
|
1964 |
|
|
FURAZOLIDONE
CHEMBL1103
|
1958 |